Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-04

Study Completion Date

2019-07-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group).

.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/topiramate in Overweight Comorbidities/obesity

NCT05209997

Overweight Obesity

WITHDRAWN

Topiramate: Long-Term Maintenance of Weight Loss Induced by Low-Calorie Diet in Obese Subjects

NCT02040311

Obesity

TERMINATED PHASE4

Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome

NCT00243984

Metabolic Syndrome X Diabetes Mellitus, Type 2

SUSPENDED PHASE3

A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity

NCT00236639

Obesity

COMPLETED PHASE3

The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight

NCT07270497

GLP-1 Nutrition

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group).

Materials and methods 200 obese patients 4 groups. had been monitored in a private clinic, each group 50 patients number, with 35 females and 15 males who were already on treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Intervention Other Names have not been specified

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

"empagliflozine", "jardiance®") "topiramate", "conviban®"

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. stable weight in the previous 6 months.
2. a sedentary lifestyle.
3. no history of diabetes mellitus.
4. taking medication that affects appetite, or weight within the past 6 months

Exclusion Criteria

1. severe anemia
2. hypothyroidism and hyperthyroidism
3. Diabetes mellitus
4. moderate to severe liver or kidney disease
5. body mass index less than 30

Minimum Eligible Age

30 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes